Please login to the form below

Not currently logged in
Email:
Password:

turoctocog alfa

This page shows the latest turoctocog alfa news and features for those working in and with pharma, biotech and healthcare.

EMA clears Novo Nordisk’s long-acting haemophilia A drug

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Esperoct (turoctocog alfa pegol) is a follow-up to Novo Nordisk’s NovoEight product and allows patients to inject themselves once every four days, rather than every other day or three

Latest news

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    Novo Nordisk’s haemophilia A treatment Esperoct (turoctocog alfa pegol), a longer-acting extended half-life factor VIII molecule, which allows patients to inject themselves once every four days, rather than

  • US approval for Novo's Factor XIII drug Tretten US approval for Novo's Factor XIII drug Tretten

    In October, Novo secured US approval for NovoEight, a new long-acting Factor VIII for people with haemophilia A (turoctocog alfa), while it also has NN7999, a long-acting recombinant coagulation ... The company suffered a disappointment last year when it

  • EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

    Novo Nordisk's haemophilia drug. Among the drugs backed by the CHMP, which provides guidance to the European Medicines Agency (EMA), was Novo Nordisk's NovoEight (turoctocog alfa) for use in

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics